Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth hormone for unexplained recurrent implantation failure in frozen embryo transfer
IRCT20201003048912N1Phase 3Completed
- Sponsor
- Avicenna Research Institute
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in Recurrent Implantation Failure (RIF) (2 arms), sponsored by Avicenna Research Institute. Primary endpoints: Clinical pregnancy, Ongoing pregnancy and 1 more. Started Jun 2020; status: completed.
02
Drugs
somatropin
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on IRCT20201003048912N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201003048912N1.